Linking CPV Enforcement Trends to Updates in Policies, SOPs and Training Linking CPV Enforcement Trends to Updates in Policies, SOPs and Training Continued Process Verification (CPV) has emerged as a pivotal element in modern pharmaceutical manufacturing, ensuring that processes remain in a state of control and are appropriately monitored throughout the product lifecycle. Over the years, the Food and Drug Administration (FDA) has reinforced the importance of CPV through various regulations and guidance, marking it as a key focus in inspections. This article aims to explore the current CPV enforcement trends as reflected in FDA 483 observations and the implications…

Structuring storyboards and evidence packs to defend CPV decisions Structuring Storyboards and Evidence Packs to Defend CPV Decisions Introduction to Continued Process Verification (CPV) Continued Process Verification (CPV) is an essential element of pharmaceutical quality systems and lifecycle management, serving to ensure that pharmaceutical manufacturing processes are consistently producing products that meet quality standards. Regulatory authorities like the FDA, the EMA, and the MHRA have increasingly emphasized the importance of CPV in their guidelines. CPV is not simply about detection of failures, but rather focuses on consistent performance and continuous improvement of drug manufacturing processes. This article addresses the crucial…

Examples of Positive Inspector Feedback on Strong CPV Practices Examples of Positive Inspector Feedback on Strong CPV Practices Continued Process Verification (CPV) represents a fundamental component in ensuring the quality and performance of pharmaceutical manufacturing processes. Regulatory bodies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and UK Medicines and Healthcare products Regulatory Agency (MHRA), have underscored the importance of rigorous CPV practices. This article delves into examples of positive inspector feedback on strong CPV practices, highlighting how these assessments can guide organizations to achieve regulatory compliance, minimize FDA 483 CPV weaknesses, and ultimately enhance product…

How to remediate CPV gaps identified during health authority inspections How to remediate CPV gaps identified during health authority inspections Continued Process Verification (CPV) has become a fundamental component of the pharmaceutical quality management system. With increased regulatory focus on CPV, understanding how to address the deficiencies identified during inspections is essential for organizations to maintain compliance and ensure product quality. This comprehensive manual aims to elucidate the strategies for remediating CPV gaps as identified during inspections by health authorities such as the FDA, EMA, and MHRA. Understanding the Regulatory Landscape for CPV The concept of CPV is integrated into…

Using CPV Enforcement Learnings to Build a Stronger, More Resilient Program Using CPV Enforcement Learnings to Build a Stronger, More Resilient Program The pharmaceutical industry is increasingly under scrutiny to ensure product quality and compliance with regulatory expectations. The concept of Continued Process Verification (CPV) has been introduced to enhance this, but it also comes with a set of responsibilities and challenges. This article aims to delve into the enforcement learnings concerning CPV by examining FDA 483s, inspection expectations, and trends across the US, UK, and EU. By understanding these elements, professionals can develop a more robust and resilient CPV…

Future enforcement focus areas likely to emerge for CPV and lifecycle control Future Enforcement Focus Areas Likely to Emerge for CPV and Lifecycle Control In the evolving landscape of pharmaceutical regulations, Continued Process Verification (CPV) has become a focal point for regulatory bodies such as the FDA, EMA, and MHRA. As the industry shifts towards a more data-driven and quality-focused paradigm, understanding the enforcement trends in CPV is crucial for professionals involved in regulatory affairs, clinical operations, and quality assurance. This article aims to unravel the complexities associated with CPV, focusing on inspection expectations, common deficiencies identified during inspections, and…

Governance structures for tracking CPV remediation to closure Governance structures for tracking CPV remediation to closure Continued Process Verification (CPV) is a critical component of the pharmaceutical manufacturing process, ensuring that products maintain consistent quality throughout their lifecycle. With increasing regulatory scrutiny, particularly from the U.S. Food and Drug Administration (FDA), effective governance structures are essential for tracking CPV remediation to closure. This article explores the governance frameworks that can be employed by pharmaceutical professionals to enhance their CPV compliance posture, address FDA 483 observations, and align with global regulatory expectations. Understanding CPV and Its Regulatory Landscape CPV is defined…

Key 483 wording every CPV program owner should know and address Key 483 Wording Every CPV Program Owner Should Know and Address In the realm of pharmaceutical manufacturing and quality assurance, Continued Process Verification (CPV) programs have emerged as essential components of lifecycle performance management. The FDA’s emphasis on CPV not only aligns with current industry expectations but also serves as a critical framework for ensuring product quality and compliance. As such, understanding the specific wording and implications of FDA Form 483 regarding CPV deficiencies is crucial for any program owner. This article aims to elucidate the key areas of…

Global Comparison of CPV Expectations Across FDA, EMA and MHRA Global Comparison of CPV Expectations Across FDA, EMA and MHRA Continued Process Verification (CPV) has emerged as a cornerstone of pharmaceutical quality management, ensuring that manufacturing processes remain in a state of control throughout the product lifecycle. This regulatory explainer manual aims to provide a comprehensive comparison of CPV expectations across key global regulatory authorities, specifically the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This comparative analysis will be invaluable to pharmaceutical professionals, clinical operations teams,…

How to use mock inspections to stress test CPV readiness How to use mock inspections to stress test CPV readiness Continued Process Verification (CPV) has become an essential component of lifecycle performance management within the pharmaceutical industry. As regulatory agencies such as the US FDA, EMA, and MHRA reinforce their expectations around CPV, stakeholders in clinical operations, regulatory affairs, and quality assurance are increasingly focusing on effective inspection readiness. This article explores the use of mock inspections as a vital tool for stress-testing CPV readiness and addressing common weaknesses observed in FDA 483 forms. Understanding the Role of Continued Process…